Comment Letter
CMS Comment Letter on Proposed Coverage Decision
Published date
CMS's January announcement proposes to cover the class of anti-amyloid mAb treatments for AD under a coverage with evidence development (CED) framework in randomized controlled trials. Our recommendations describe opportunities for CMS to refine their proposed coverage decision in light of the evolving body of evidence for mAb treatments and to address the priorities of patient access, equity, and further needed evidence development.
Duke-Margolis Authors
Mark McClellan, MD, PhD
Director of the Duke-Margolis Institute for Health Policy
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty
Marianne Hamilton Lopez, PhD, MPA
Senior Research Director, Biomedical Innovation
Faculty Director of the Duke-Margolis Postdoctoral Associates & Affiliated Fellows Program
Adjunct Associate Professor
Senior Team Member
Margolis Core Faculty
Beena Bhuiyan Khan, MSc
Research Director for Payment and Coverage Policy
Nitzan Arad, LLM
Area Lead for Drug Pricing and Competition Policy
Hannah Graunke, MPP
Senior Policy Analyst
